Laura Prendergast
Stock Analyst at Raymond James
(0.39)
# 4,182
Out of 5,005 analysts
7
Total ratings
33.33%
Success rate
-19.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Initiates: Outperform | $5 | $2.42 | +106.61% | 1 | Mar 26, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.08 | +765.38% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.13 | +651.17% | 2 | Aug 14, 2024 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | $20 | $3.89 | +414.14% | 1 | Jul 31, 2024 | |
| RVMD Revolution Medicines | Upgrades: Strong Buy | $36 → $48 | $46.71 | +2.76% | 2 | Apr 10, 2024 |
Erasca
Mar 26, 2025
Initiates: Outperform
Price Target: $5
Current: $2.42
Upside: +106.61%
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.08
Upside: +765.38%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.13
Upside: +651.17%
Black Diamond Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: $20
Current: $3.89
Upside: +414.14%
Revolution Medicines
Apr 10, 2024
Upgrades: Strong Buy
Price Target: $36 → $48
Current: $46.71
Upside: +2.76%